Summary: Researchers have identified the key mechanism behind IgLON5 encephalitis (Anti-IgLON5 disease). Using antibodies taken from patients and applied to neuronal cell cultures and mice, the team demonstrated a direct causal connection between autoimmune attacks on the cell-surface protein IgLON5 and the harmful aggregation of Tau proteins inside neurons.
This discovery shows that the disease is driven by abnormal neuronal hyperactivity, revealing a potential new target for therapeutic intervention.
Key Facts
- The causal mechanism: Patient-derived antibodies bind to IgLON5 on the neuronal surface, forcing these proteins to cluster with other membrane proteins and triggering an intracellular cascade that damages neurons.
- Neuronal hyperactivity: Surface protein clustering provokes abnormal neuronal hyperactivity; the researchers identify this hyperexcitability as the primary driver of downstream neurodegeneration.
- Tau pathology initiated: The resulting hyperactivity causes Tau proteins to dissociate from the neuronal cytoskeleton, mislocalize, become abnormally phosphorylated and aggregate—processes that mirror pathological Tau changes seen in other neurodegenerative diseases such as Alzheimer’s disease.
- Therapeutic implications: Because Anti-IgLON5 disease often presents with a complex and varied phenotype that delays diagnosis, therapeutically targeting the neuronal hyperactivity revealed here could open a novel route for treatment development.
Source: DZNE
What is IgLON5 encephalitis? In IgLON5 encephalitis the immune system mistakenly attacks proteins on the surface of neurons. This autoimmune response produces brain inflammation and neuronal damage that can present as severe sleep disorders, cognitive decline and movement problems.
Scientists at the German Center for Neurodegenerative Diseases (DZNE) and Charité – Universitätsmedizin Berlin have now uncovered the fundamental steps that link the immune attack to the neuronal Tau pathology characteristic of this rare but serious disease.
The research, published in the journal Science Advances, used patient-derived anti-IgLON5 antibodies applied to cultured neurons and to wild-type mice. These experiments revealed how antibodies targeting the neuronal surface protein IgLON5 set off changes that culminate in Tau aggregation inside neurons—a key pathological hallmark.
Previously, it was not understood how an immune attack at the cell surface could provoke the formation of intracellular Tau aggregates. The new data show that when aberrant antibodies bind IgLON5, they force these molecules to cluster with other membrane proteins. That clustering sends abnormal signals into the neuron, producing sustained hyperactivity. This excessive excitability stresses neuronal systems and leads to Tau detachment from the cytoskeleton, mislocalization, abnormal phosphorylation and aggregation.
“Our results establish a causal link between IgLON5-targeting antibodies and Tau pathology,” explains Prof. Susanne Wegmann, a research group leader at DZNE and Charité. The study demonstrates that antibody-induced membrane clustering and the resulting hyperexcitability are sufficient to trigger Tau changes that are toxic to neurons.
Pathological Tau aggregation is not unique to Anti-IgLON5 disease; it is also central to Alzheimer’s disease, where neuronal hyperactivity—often linked to amyloid-beta pathology—is thought to promote toxic Tau alterations. The parallels between these diseases suggest that understanding and controlling hyperexcitability could have broader relevance for multiple Tau-related neurodegenerative disorders.
A potential treatment approach
Anti-IgLON5 disease was first described in 2014 and remains rare. Its varied clinical presentation makes early diagnosis difficult, and without timely treatment the condition can lead to severe disability or premature death. Current approaches include immunosuppression and supportive care, but outcomes are often limited.
By pinpointing neuronal hyperactivity as a previously unrecognized driver of pathology in Anti-IgLON5 disease, the study highlights a new therapeutic target: interventions that reduce neuronal hyperexcitability could potentially prevent or limit Tau mislocalization and aggregation, slowing disease progression.
Key Questions Answered:
A: First described in 2014, IgLON5 encephalitis is a rare autoimmune brain disease in which antibodies attack neuronal surface proteins. The resulting inflammation and neuronal damage produce sleep disturbances, cognitive decline and movement disorders; untreated, the disease can cause severe disability or premature death.
A: When antibodies bind IgLON5 on the cell surface they force these proteins to cluster, which triggers aberrant signaling and sustained neuronal hyperactivity. That hyperactivity in turn causes intracellular Tau proteins to dissociate from their normal cytoskeletal anchoring, become missorted and aggregate, creating toxic intracellular deposits.
A: Yes. Alzheimer’s disease is also associated with neuronal hyperactivity that is thought to promote toxic changes in Tau. Because the IgLON5 pathway links surface immune attack, hyperexcitability and Tau aggregation, it provides a model for studying how hyperactivity drives Tau pathology and may point to strategies relevant across multiple neurodegenerative disorders.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The underlying journal paper was read and reviewed in full.
- Additional context and clarification were added by editorial staff.
About this neurology research news
Author: Marcus Neitzert
Source: DZNE
Contact: Marcus Neitzert – DZNE
Image: The image is credited to Neuroscience News
Original Research: Open access. “IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity” by Bilge Askin et al., published in Science Advances. DOI: 10.1126/sciadv.aec2042
Abstract
IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity
Anti-IgLON5 disease is an autoimmune disorder in which autoantibodies against the neuronal cell-surface protein IgLON5 lead to severe brain dysfunction and Tau pathology. How these antibodies cause Tau abnormalities and neurodegeneration was previously unclear.
The study shows that patient-derived anti-IgLON5 antibodies cluster IgLON5 with other surface proteins, inducing neuronal hyperactivity that triggers pathological Tau missorting and phosphorylation—changes typically observed early in Tau-related neurodegenerative diseases. In wild-type mice, exposure to these antibodies produced hippocampal Tau phosphorylation and neuroinflammatory responses.
These findings establish a causal connection between anti-IgLON5 antibodies and Tau pathology in affected patients and highlight neuronal hyperactivity as an overarching driver of Tau-related disease processes, presenting a promising avenue for therapeutic development.